A new publication involving etelcalcetide was published on August 11, 2026, in Frontiers in Immunology. The paper is titled "Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential." It addresses calcimimetics, including etelcalcetide, in the context of chronic kidney disease mineral and bone disorder, known as CKD-MBD. The title indicates the publication covers calcium-sensing receptor, or CaSR, signaling and its relation to interactions among bone, immune, and vascular systems. The publication also references therapeutic potential as part of its scope, according to the title provided.
This entry reflects only the publication details supplied: the title, the journal name, and the publication date. No findings, conclusions, or data from the study are described here. Readers interested in the specific content, methodology, or results of this paper should consult the original publication directly through the listed source.
For general background on etelcalcetide, including its approved regulatory status and its role among calcimimetic therapies, readers can consult the compound overview for additional context.